Horizon Investment Services LLC boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 204.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,466 shares of the biopharmaceutical company's stock after buying an additional 9,707 shares during the period. Horizon Investment Services LLC's holdings in Halozyme Therapeutics were worth $923,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Gallacher Capital Management LLC raised its holdings in Halozyme Therapeutics by 19.4% during the 1st quarter. Gallacher Capital Management LLC now owns 7,793 shares of the biopharmaceutical company's stock valued at $497,000 after buying an additional 1,267 shares during the last quarter. IFP Advisors Inc grew its position in shares of Halozyme Therapeutics by 2,374.1% during the 1st quarter. IFP Advisors Inc now owns 2,103 shares of the biopharmaceutical company's stock valued at $134,000 after acquiring an additional 2,018 shares during the period. Kestra Private Wealth Services LLC raised its stake in Halozyme Therapeutics by 10.8% during the 1st quarter. Kestra Private Wealth Services LLC now owns 10,318 shares of the biopharmaceutical company's stock worth $658,000 after acquiring an additional 1,004 shares during the period. Bernzott Capital Advisors grew its holdings in Halozyme Therapeutics by 8.3% during the 1st quarter. Bernzott Capital Advisors now owns 101,760 shares of the biopharmaceutical company's stock valued at $6,493,000 after buying an additional 7,775 shares in the last quarter. Finally, Diversify Advisory Services LLC lifted its holdings in shares of Halozyme Therapeutics by 6.5% in the 1st quarter. Diversify Advisory Services LLC now owns 6,202 shares of the biopharmaceutical company's stock valued at $377,000 after acquiring an additional 377 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.
Halozyme Therapeutics Price Performance
Shares of HALO traded down $0.53 during trading hours on Monday, hitting $55.92. 1,051,767 shares of the company were exchanged, compared to its average volume of 1,753,333. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $70.51. The company has a quick ratio of 7.30, a current ratio of 8.39 and a debt-to-equity ratio of 3.13. The firm's fifty day moving average is $54.29 and its 200 day moving average is $57.34. The company has a market cap of $6.89 billion, a price-to-earnings ratio of 14.87, a P/E/G ratio of 0.38 and a beta of 1.15.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. The company had revenue of $264.86 million during the quarter, compared to the consensus estimate of $231.21 million. During the same period last year, the business posted $0.79 earnings per share. Halozyme Therapeutics's revenue was up 35.2% on a year-over-year basis. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on HALO shares. Wells Fargo & Company upped their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research note on Wednesday, May 7th. The Goldman Sachs Group started coverage on Halozyme Therapeutics in a research note on Thursday, July 10th. They set a "neutral" rating and a $55.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, May 29th. Benchmark lowered Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. Finally, Leerink Partners cut shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a report on Tuesday, May 13th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $62.70.
Read Our Latest Analysis on HALO
Insider Transactions at Halozyme Therapeutics
In related news, Director Jeffrey William Henderson sold 4,497 shares of the business's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the transaction, the director directly owned 28,611 shares in the company, valued at $1,727,246.07. The trade was a 13.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $56.43, for a total value of $1,128,600.00. Following the completion of the transaction, the chief executive officer directly owned 733,719 shares of the company's stock, valued at approximately $41,403,763.17. This trade represents a 2.65% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 64,497 shares of company stock valued at $3,533,884. 2.90% of the stock is owned by insiders.
About Halozyme Therapeutics
(
Free Report)
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Recommended Stories
Before you consider Halozyme Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Halozyme Therapeutics wasn't on the list.
While Halozyme Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
